Brokerages Set Agilent Technologies, Inc. (NYSE:A) Price Target at $160.93

Agilent Technologies, Inc. (NYSE:A) has earned an average recommendation of “Moderate Buy” from the seventeen analysts that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $160.9333.

Several analysts recently commented on A shares. TD Cowen boosted their price target on Agilent Technologies from $147.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Piper Sandler started coverage on Agilent Technologies in a research report on Thursday, June 11th. They set a “neutral” rating and a $150.00 price target for the company. Robert W. Baird boosted their price target on Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 26th. Morgan Stanley dropped their price target on Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Finally, Wolfe Research reiterated a “hold” rating on shares of Agilent Technologies in a research report on Tuesday, June 2nd.

Agilent Technologies Stock Down 0.6%

Shares of A opened at $126.34 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. Agilent Technologies has a one year low of $108.35 and a one year high of $160.27. The stock has a market capitalization of $35.68 billion, a price-to-earnings ratio of 25.37, a PEG ratio of 2.26 and a beta of 1.26. The stock has a 50 day moving average price of $121.70 and a 200 day moving average price of $126.60.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping the consensus estimate of $1.41 by $0.08. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The firm had revenue of $1.84 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the previous year, the business earned $1.31 earnings per share. The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. Equities research analysts forecast that Agilent Technologies will post 6 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.255 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $1.02 dividend on an annualized basis and a yield of 0.8%. Agilent Technologies’s payout ratio is 20.48%.

Hedge Funds Weigh In On Agilent Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in A. Norges Bank acquired a new position in Agilent Technologies during the fourth quarter worth $549,158,000. Massachusetts Financial Services Co. MA boosted its stake in Agilent Technologies by 13.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company’s stock worth $1,925,064,000 after buying an additional 1,713,216 shares during the last quarter. AQR Capital Management LLC boosted its stake in Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock worth $240,956,000 after buying an additional 1,652,244 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in Agilent Technologies by 132.2% during the second quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock worth $277,807,000 after buying an additional 1,340,161 shares during the last quarter. Finally, Balyasny Asset Management L.P. boosted its stake in Agilent Technologies by 192.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,412,535 shares of the medical research company’s stock worth $192,204,000 after buying an additional 928,821 shares during the last quarter.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.